Vivione Biosciences Signs MOU with AriBio, Inc.

Vivione Biosciences Inc. (TSXV:VBI) signed a Memorandum of Understanding with South Korean biotech company, AriBio, Inc. This strategic alliance combines the strengths of Vivione in the areas of rapid diagnostics and its new in silico compound modeling technology with AriBio’s substantial experience in drug design and testing.
As quoted in the press release:

“We see this as a win-win for both companies,” said Vivione’s Chief Executive Officer, Kevin Kuykendall. “AriBio can assist Vivione with accessing the lucrative Asian market and Vivione can help AriBio with companion diagnostics and in silico compound design.”
Building on the Cooperative Research and Development Agreement that was signed with the FDA last year, this partnership marks another milestone for Vivione as being its first prospective alliance with a drug development company. The alliance could benefit AriBio by accelerating the drug development process via specific Vivione intellectual property, Molecular Design, which has the potential to enable accurate computer modeling of the efficacy and potential toxicities of compounds. Vivione expects the alliance will expand their food safety footprint beyond the frontline product, the RAPID-B diagnostic platform, and into companion clinical diagnostics with the potential for growth opportunities in the Asian market.

Click here to read the Vivione Biosciences Inc. (TSXV:VBI) press release